| Ambrisentan Improves Exercise Capacity and Symptoms in Patients with Portopulmonary Hypertension. | |
| | |
MedLine Citation:
|
PMID: 21887662 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
INTRODUCTION: Ambrisentan, a selective endothelin receptor antagonist has been approved in several countries for pulmonary arterial hypertension. No data have been published on the efficacy of ambrisentan on improvement of exercise capacity in patients with portopulmonary hypertension (PoPH). PATIENTS AND METHODS: We retrospectively analyzed the safety and efficacy of ambrisentan in patients with PoPH in four German university hospitals. RESULTS: 14 patients with moderate to severe PoPH were included. The median follow-up was 16 months (IQR, 12 - 21). 6 minute walk tests after 6 and 12 months improved from 376 meters (IQR, 207 - 440) at baseline to 415 meters (IQR, 393 - 475; p = 0.011) and 413 meters (IQR, 362 - 473, p = 0.005), respectively. WHO- functional class after 1 year of therapy with ambrisentan also improved significantly (p = 0.014). No significant changes in blood gas analysis and liver function tests (aspartate aminotransferase, alanine aminotransferase, total bilirubin, and international normalized ratio) during therapy with ambrisentan were detectable. CONCLUSIONS: The present study demonstrates significant improvement of exercise capacity and clinical symptoms without relevant safety concerns during ambrisentan treatment in patients with PoPH. |
| | |
Authors:
|
M Halank; L Knudsen; H-J Seyfarth; R Ewert; B Wiedemann; M Kolditz; G Höffken; M M Hoeper |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-1 |
Journal Detail:
|
Title: Zeitschrift fur Gastroenterologie Volume: 49 ISSN: 1439-7803 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-9-2 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0033370 Medline TA: Z Gastroenterol Country: - |
Other Details:
|
Languages: ENG Pagination: 1258-1262 Citation Subset: - |
Copyright Information:
|
© Georg Thieme Verlag KG Stuttgart · New York. |
Affiliation:
|
Department of Internal Medicine I, University Hospital Carl Gustav Carus of TU Dresden, Germany. |
Vernacular Title:
|
Ambrisentan verbessert die Belastbarkeit und Symptomatik bei Patienten mit portopulmonaler Hypertonie. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hepatitis E: An Emerging Infectious Disease in Germany?
Next Document: Acute Pancreatitis in a Patient with Hypercalcemia due to Tertiary Hyperparathyroidism.